Funding of £16 million over five years for cancer-drug programmes at the Paterson Institute in Manchester and the Beatson Institute in Glasgow have been announced by Cancer Research UK.
It has also awarded £2.5 million each to the University of Southampton and the University of Oxford to initiate new research into therapeutic antibodies stimulate the body’s immune system.
The investments are intended to increase the charity’s scope and expertise in small-molecule drug-discovery programmes, and are direct results of a new strategic initiative.
They focus on developing new chemical compounds to stop the growth and spread of cancer, while increasing the range of antibody therapies available to promote immune responses against the disease.
Says spokesman Dr Peter Sneddon: “It’s extremely exciting to be able to invest in such high-level drug-discovery projects. The two new programmes will strengthen the charity’s capability in this crucial area of research, and will be able to harness the charity’s basic-science expertise to discover potential new treatments that will help fight cancer.”
Copyright Press Association 2009